AzTrials
AzTrials

Abnormal Uterine BleedingBARHYSTERNCT06024109

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

An observational study of Abnormal Uterine Bleeding and Endometriosis, run by Aesculap AG at 2 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
Closure of the Vaginal Cuff after Total Hysterectomy
Type of treatment
Medical device
How many people
132 participants
Where
2 sitesin 2 countries
Study dates
19 Mar 2024to Aug 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Female patients undergoing an elective, laparoscopic total hysterectomy

Who may be able to join

  • Females undergoing an elective, laparoscopic total hysterectomy
  • Age ≥ 18 years
  • Written informed consent

Who cannot join

  • Emergency surgery
  • Open surgery
  • Patients undergone immunosuppressive drug treatment within the prior 6 months
  • Patients with hypersensitivity or allergy to the suture material.
  • Participation in another clinical study
  • Non-compliance of patient

Trial locations and contacts

2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

2 sites in 2 countries

Germany1 site, 1 recruiting
  • Klinikum Sachsenhausen der DGD

    Frankfurt am Main, Hesse, 60594

    Amadeus Hornemann, Prof. Dr.

    Amadeus Hornemann, Prof. Dr.

    Recruiting

Other trials in Germany

Spain1 site, 1 recruiting
  • Hospital Sant Joan de Déu de Manresa

    Manresa, Barcelona, 08243

    Lourdes Hinojosa Sánchez, Dra.

    Lourdes Hinojosa Sánchez, Dra.

    Recruiting

Other trials in Spain

About this study

Official title: Prospective, International, Randomized, Multicentric, Controlled Study on the Performance of SYMMCORA® Mid-term Unidirectional Barbed Suture Versus V-loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate.

Secondly, the superiority of SYMMCORA®, mid-term unidirectional compared to the V-Loc®, unidirectional will be assessed regarding the mean time to close the vaginal cuff. The study will be performed in routine clinical setting, the only difference will be the randomization into two different suture groups. Both suture materials which will be applied to approximate the vaginal cuff are approved and carrying the CE-marks. Additionally, both sutures will be applied in their intended use. Neither additional invasive measures nor additional burden in regard to the patient will be performed.

Being tested
Closure of the Vaginal Cuff after Total Hysterectomy
Keywords
Barbed Suture, Hysterectomy, Laparoscopy, Minimal Invasive
Medical subject headings
Metrorrhagia, Endometriosis, Uterine Prolapse, Uterine Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Closure of the Vaginal Cuff after Total HysterectomyDevice

    Also called Suturing

    Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).

Study groups in NCT06024109
Study groupRoleWhat they receive
SYMMCORA®Barbed suture SYMMCORA® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
Receives: Device: Closure of the Vaginal Cuff after Total Hysterectomy
V-Loc®Barbed suture V-Loc® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
Receives: Device: Closure of the Vaginal Cuff after Total Hysterectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Suturing time to close the vaginal cuff

    Measured in Minutes. Time to perform the vaginal cuff closure after laparoscopic total hysterectomy using a stop watch. Time starts when the needle passes the first time the tissue and ends after completion of the wound closure (cut of the needle from the thread).

    Measured: intraoperatively

Secondary outcomes (16)
  1. Number of patients with early complications

    Documented early complications include Hemoglobin drop and Fever more than 38°C within 48 hours

    Measured: at discharge (up to 10 days after surgery)

  2. Number of patients with complications over the study period

    Documented complications include Vaginal cuff infection, Vaginal cuff dehiscence (Defined as a visually confirmed partial or complete opening of the vaginal stump with or without visceral organ herniation), Vaginal cuff granulation formation, Pelvic Abscess Formation, Hematoma, Vaginal spotting (defined as bloody vaginal discharge that did not require extraordinary procedures or medication and disappeared spontaneously. (Days of postoperative bleeding, Number of pads / tampons used), Vaginal bleeding (Defined as postoperative vaginal stump bleeding that required additional stump suture to stop bleeding. (Days of postoperative bleeding, number of pads / tampons used), Urinary tract infection, Bladder injury, Ureter injury, Bowel obstruction, Ileus, Cystitis and Pelvic Adhesions.

    Measured: at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively

  3. Number of patients with device deficiencies over the study period

    Documented device deficiencies include Suture rupture, Knots in the thread, Connection between needle and thread not intact and Disconnection of the anchor from the thread

    Measured: intraoperatively, at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively

  4. Patient satisfaction (VAS 0-100) over time

    The patient's self assessment of her satisfaction with the surgery. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "low" and "100" at the opposite end representing "high". The value is measured in [mm] with a ruler and documented in whole numbers.

    Measured: at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively

  5. Progress of Female Sexual Function Index (FSFI) compared to baseline

    The Female Sexual Function Index (FSFI) is a 19-item, self-report measure of female sexual function that provides scores on overall levels of sexual function as well as the primary components of sexual function in women, including sexual desire, arousal, orgasm, pain, and satisfaction. The 19 items of the FSFI use a 5-point Likert scale ranging from 1-5 with higher scores indicating greater levels of sexual functioning on the respective item. (0 points in some cases for items that are not applicable). To score the measure, the sum of each domain score is first multiplied by a domain factor ratio (0.6 for desire; 0.3 for arousal and lubrication; 0.4 for orgasm, satisfaction and pain) in order to place all domain totals on a more comparable scale, and then subsequently summed to derive a total FSFI score. The domain scores range from 1.2 - 6, the overall score ranges from 7.2 - 36.

    Measured: Preoperatively (baseline), at follow-up visits 6-8 weeks postoperatively and 6 months postoperatively

  6. Overall operation time

    From the first cut to the end of the surgery

    Measured: intraoperatively

  7. Cost of treatment

    Calculation using the length of hospitalization (days until discharge), suturing time, suture costs and needed transfusions)

    Measured: at discharge (approximately 10 days after surgery)

  8. Length of postoperative hospital stay

    calculated by subtracting the surgery date from the date of discharge

    Measured: at discharge (approximately 10 days after surgery)

  9. Progress of Patient's abdominal pain (VAS 0-100) compared to baseline

    The patient's self assessment of her abdominal pain. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain". The value is measured in [mm] with a ruler and documented in whole numbers

    Measured: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively

  10. Progress of Patient's pelvic pain (VAS 0-100) compared to baseline

    The patient's self assessment of her pelvic pain. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain". The value is measured in [mm] with a ruler and documented in whole numbers

    Measured: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively

  11. Progress of Patient's lumbar pain (VAS 0-100) compared to baseline

    The patient's self assessment of her lumbar pain. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain". The value is measured in [mm] with a ruler and documented in whole numbers

    Measured: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively

  12. Progress of General Health Status compared to baseline

    The patient's self assessment of her general health status. Health status is based on assessment of the patient to the question, "Would you say your health in general is...:" The options are excellent / very good / good / fair / poor

    Measured: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively

  13. Patient assessment of postoperative Dyspareunia

    Dyspareunia is defined by genital pain that can be experienced before, during, or after intercourse. The patient answers with yes or no.

    Measured: at both follow-up visits (6-8 weeks postoperatively and 6 months postoperatively)

  14. Assessment of the handling of the barbed suture (SYMMCORA®)

    Assessment of the handling of the unidirectional barbed suture (SYMMCORA®) intra-operatively including eleven different dimensions (pliability, Pass-through, traumaticity, anchoring capacity, safety of closure, locking system size, locking system deployment, locking system unbarbed area, locking system safety of closure, atraumaticity, wound closure approximation) and an overall impression with 5 evaluations levels (excellent, very good, good, satisfied, poor).

    Measured: intraoperatively

  15. Assessment of the handling of the barbed suture (SYMMCORA®) compared to conventional suture

    Assessment of the handling of the barbed suture (SYMMCORA®) compared to conventional suture regarding degree of difficulties and the ease of handling. (Likert Scale: strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).

    Measured: intraoperatively

  16. Assessment of the handling of the barbed suture (SYMMCORA®) compared to barbed suture (V-Loc)

    Assessment of the barbed suture (SYMMCORA®) compared to barbed suture (V-Loc®) regarding smoothness, suppleness, traumaticity of the thread, the handling, the opening of the package and the overall opinion (Likert Scale: worse, equal, better).

    Measured: intraoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Sep 2023
  2. Study start19 Mar 2024
  3. Primary completionJan 2027 (estimated)
  4. Study completionAug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
132 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06024109
Sponsor's protocol ID
AAG-O-H-2001
Acronym
BARHYSTER
Status last verified
Jun 2026
First submitted
15 Aug 2023
Last updated
2 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Baumann P, Sanchez LH, Garcia NG, Sologiuc L, Hornemann A. Assessment of a novel unidirectional mid-term absorbable barbed suture versus a competitor barbed suture for vaginal cuff closure after gynaecology surgery, study protocol of a randomized controlled trial - BARHYSTER. BMC Surg. 2025 Jan 14;25(1):23. doi: 10.1186/s12893-024-02700-z.

    PubMed 39806425

Questions about this trial

What is this clinical trial studying?

An observational study of Abnormal Uterine Bleeding and Endometriosis, run by Aesculap AG at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Petra Baumann (+49746195 ext. 1646, petra.baumann@aesculap.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Suturing time to close the vaginal cuff (time frame: intraoperatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06024109, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in